Anemia, Refractory, With Excess of Blasts Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook

Published August 26, 2026 · Evidence accessed through Patsnap Life Sciences MCP servers.

This report evaluates one indication only: Anemia, Refractory, With Excess of Blasts. It connects disease background, epidemiology, target mechanism, competition, transactions, unmet need and market attractiveness.

Build evidence-backed indication strategy with Patsnap MCP

Connect disease, target, clinical-trial and transaction intelligence through the Patsnap Life Sciences MCP marketplace.

Executive assessment

Anemia, Refractory, With Excess of Blasts receives a directional score of 58/100, combining unmet need (73/100), competitive intensity (96/100) and market attractiveness (80/100). It is a prioritization framework, not a revenue forecast or medical recommendation.

Disease background and strategic definition

Chronic refractory anemia with granulocytopenia, and/or thrombocytopenia. Myeloblasts and progranulocytes constitute 5 to 40 percent of the nucleated marrow cells.

The reproducible record is Patsnap disease ID d39b64a7a7714a9f9227c3607e801e41 and MeSH identifier D000754. Stable identifiers prevent historical names, gene-defined subtypes and overlapping syndromic labels from producing inconsistent landscapes.

A target product profile should define phenotype, age, severity, diagnostic confirmation, prior therapy, setting, safety and endpoint. An overly broad population can inflate market size while weakening biological signal and recruitment. The first population should be biologically coherent and operationally feasible.

Map the pathway from symptom recognition through specialist referral, testing, treatment and monitoring. Diagnostic delay, center concentration and testing access can constrain trials and commercialization as much as drug performance.

Epidemiology and disease burden

Epidemiology evidence 1: CCDC Weekly Reports (Vol. 8 No. 10 Mar. 6, 2026) Shifting Patterns of Anemia Prevalence and Severity AmongUrban Women — China, 2019–2024

prevalence estimates with 95% confidence intervals (CIs) were calculated by adjusting for provincial population structures. Temporal changes were quantified using prevalence differences with corresponding 95% CIs. Multivariable logistic regression models incorporating time-by-covariate interaction terms were employed to identify factors associated with anemia and moderate-to-severe anemia and to assess time-varying associations. Results: Between 2019 and 2024, the overall prevalence of anemia among urban women and women of reproductive age in China declined from 13.7% (95% CI: 13.0, 14.4) and 17.0% (95% CI: 16.3, 17.8) to 13.2% (95% CI: 12.7, 13.8) and 16.7% (95% CI: 16.1, 17.3), respectively, while moderate-to-severe anemia prevalence remained essentially unchanged. Among women aged 40–49 years, anemia prevalence increased modestly, with a statistically significant rise in moderate-to-severe anemia of 0.32 percentage points (95% CI: 0.06, 0.57). Substantial regional disparities persisted: anemia prevalence decreased in 18 provincial units but increased in the remaining 13 units. Among women of reproductive age, anemia prevalence rose in 14 provincial units, with three provinces reaching or exceeding the 20% threshold indicative of moderate public health burden. Conclusion: Although China has achieved modest progress in reducing anemia among women, the overall disease burden remains substantial, with persistently elevated or increasing prevalence observed in specific subpopulations. These findings underscore the urgent need for targeted, risk-stratified public health interv

Review source

Epidemiology evidence 2: Anemia Prevalence: United States, August 2021–August 2023

Anemia Prevalence: United States, August 2021–August 2023 Anne M. Williams, Ph.D., M.P.H., Nicholas Ansai, M.P.H., Namanjeet Ahluwalia, Ph.D., D.Sc., and Duong T. Nguyen, D.O. Anemia is a condition in which not enough red blood cells are available to deliver oxygen to the body, which can cause fatigue and shortness of breath (1). Severe anemia is a risk factor for adverse health outcomes ranging from poor child development to maternal mortality (2,3). Anemia can result from many causes, including iron deficiency, chronic or infectious diseases, or inherited blood disorders such as thalassemia (1,4). This report provides estimates of anemia in those age 2 years and older by selected characteristics during the August 2021–August 2023 National Health and Nutrition Examination Survey (NHANES). Key findings Key findings Data from the National Health and Nutrition Examination Survey ●During August 2021–August 2023, the overall prevalence of anemia in people age 2 years and older was 9.3%. Prevalence was higher in females (13.0%) than in males (5.5%). What was the prevalence of anemia during August 2021– August 2023, and were differences observed by age and sex? ●Anemia prevalence was lowest in children ages 2–11 (4.7%) and highest in adults 60 and older (12.5%). In August 2021–August 2023, the prevalence of anemia was 9.3% in those age 2 years and older (Figure 1, Table 1). The prevalence was higher in females ●Anemia prevalence was highest in Black non-Hispanic females (31.4%) and Black non-Hispanic males (10.8%) age 2 and older compared with all other race and Hispanic- origin

Review source

Epidemiology evidence 3: Prevalence and incidence of primary autoimmune hemolytic anemia and cold agglutinin disease in the United States, 2016–2023

1. DelveInsight. Warm autoimmune hemolytic anemia epidemiology forecast segmentation, treatment approaches, and WAIHA market forecast [Internet]. 2020 April 3 [cited Feb 15, 2024]. Available from: https://www.delveinsight.com/blog/ warm-autoimmune-ahemolytic-anemia-epidemiology-forecast 2. Hansen DL, Möller S, Andersen K, Gaist D, Frederiksen H. Increasing incidence and prevalence of acquired hemolytic anemias in Denmark, 1980- 2016. Clin Epidemiol. 2020;12:497–508. 3. Bylsma LC, Gulbech Ording A, Rosenthal A, Öztürk B, Fryzek JP, Arias JM, et al. Occurrence, thromboembolic risk, and mortality in Danish patients with cold agglutinin disease. Blood Adv. 2019;3(20):2980–5. https://doi-org.libproxy1.nus.edu.sg/10.1182/bloodadvances.2019000476 PMID: 31648316 4. Hematology, ASH® Education Program. Autoimmune hemolytic anemia [Internet]. 2018 November 30 [cited Feb 15, 2024]. Available from: https:// ashpublications.org/hematology/article/2018/1/382/277583/Autoimmune-hemolytic-anemia 5. National Organization for Rare Disorders (NORD). [cited Feb 15, 2024]. Available from: https://rarediseases.org/. 6. Zanella A, Barcellini W. Treatment of autoimmune hemolytic anemias. Haematologica. 2014;99(10):1547–54. https://doi-org.libproxy1.nus.edu.sg/10.3324/haema­ tol.2014.114561 PMID: 25271314 7. Barcellini W, Fattizzo B. The Changing Landscape of Autoimmune Hemolytic Anemia. Front Immunol. 2020;11:946. https://doi-org.libproxy1.nus.edu.sg/10.3389/ fimmu.2020.00946 PMID: 32655543 8. Berentsen S. Cold agglutinin disease. Hematology Am Soc Hematol Educ Program. 2016;2016(1):226–31. https://doi-org.libproxy1.nus.edu.sg/10.1182/asheduca­ tion-2016.1.226 PMID: 27913484 9. Mic

Review source

Convert population evidence into a funnel: total affected → diagnosed → clinically eligible → treated → realistically accessible. Incidence, point prevalence and lifetime prevalence are not interchangeable. Do not pool incompatible age bands, case definitions or health systems.

For Anemia, Refractory, With Excess of Blasts, quantify diagnostic yield, severity distribution, center concentration, treatment penetration, survival and progression. Use conservative, base and upside ranges with a source and access date for every parameter. Market models should show which assumptions drive recruitment and adoption.

A small, well-defined population concentrated in expert centers may be more actionable than a larger population with poor diagnosis. Epidemiology therefore must connect to real patient identification, clinical eligibility and access.

Unmet need and patient-value thesis

Unmet need should identify a specific failure: progression, incomplete control, toxicity, weak durability, burdensome delivery, diagnostic delay or absent options for a subgroup. Disease severity alone does not demonstrate that a program can deliver measurable benefit.

A strong Anemia, Refractory, With Excess of Blasts thesis connects mechanism to a prospectively defined responder population and an endpoint understood by regulators, clinicians, patients and payers. It tests whether benefit is measurable within a feasible period and whether natural-history variability can be controlled.

Proceed through gates: confirm phenotype and natural history, demonstrate engagement, observe pharmacodynamic response, show interpretable clinical signal and only then scale. Pre-agreed stop criteria protect capital and make negative studies informative.

Target mechanism anchor: C5

Precursor of the C5a anaphylatoxin and complement C5b components of the complement pathways, which consist in a cascade of proteins that leads to phagocytosis and breakdown of pathogens and signaling that strengthens the adaptive immune system (PubMed:12878586, PubMed:18204047, PubMed:30643019, PubMed:6554279). Activated downstream of classical, alternative, lectin and GZMK complement pathways (PubMed:12878586, PubMed:18204047, PubMed:30643019, PubMed:39914456, PubMed:39814882, PubMed:6554279). Component of the membrane attack complex (MAC), a multiprotein complex activated by the complement cascade, which inserts into a target cell membrane and forms a pore, leading to target cell membrane rupture and cell lysis (PubMed:26841837, PubMed:27052168, PubMed:30552328, PubMed:30643019). Complement C5b is generated following cleavage by C5 convertase and initiates formation of the MAC complex: C5b binds sequentially C6, C7, C8 and multiple copies of the pore-forming subunit C9 (PubMed:30552328, PubMed:30643019). During MAC complex assembly, the C5b6 subcomplex, composed of complement C5b and C6, associates with the outer leaflet of target cell membrane, reducing the energy for membrane bending (PubMed:30552328, PubMed:32569291). Mediator of local inflammatory process released following cleavage by C5 convertase (PubMed:8182049, PubMed:9553099). Acts by binding to its receptor (C5AR1 or C5AR2), activating G protein-coupled receptor signaling and inducing a variety of responses including intracellular calcium release, contraction of smooth muscle, increased vascular permeability, and histamine release from mast cells and basophilic leukocytes (PubMed:36806352, PubMed:37852260, PubMed:37169960, PubMed:8182049, PubMed:9553099). C5a is also a potent chemokine which stimulates the locomotion of polymorphonuclear leukocytes and directs their migration toward sites of inflammation (PubMed:342601, PubMed:37852260, PubMed:37169960, PubMed:5765461, PubMed:8182049, PubMed:9553099).

The mechanism anchor is C5, a testable pathway hypothesis rather than a claim that every patient is target-dependent. Establish tissue expression, human genetic or biomarker support, pharmacologic tractability, target engagement, downstream modulation and therapeutic window.

Use orthogonal engagement assays, disease-relevant dose–response studies, biomarker qualification, compensatory-pathway analysis and explicit safety testing. Human evidence should carry more weight than model-only observations. Related failures should be analyzed for exposure, population and endpoint lessons.

A go decision requires a complete chain from relevant biology to achievable modulation, measurable pharmacodynamics and a plausible bridge to clinical benefit. Missing links require targeted experiments, not stronger narrative.

Build evidence-backed indication strategy with Patsnap MCP

Connect disease, target, clinical-trial and transaction intelligence through the Patsnap Life Sciences MCP marketplace.

Clinical development and competition

The focused search returned 298 registered studies.

• NCT07565220 — Thiotepa-based Conditioning Regimen With De-escalated Post-graft Cyclophosphamide for Allogeneic Stem Cell Transplantation in Hematologic Malignancies; Recruiting; Phase 1; sponsor University of Pittsburgh; enrollment 48.
• NCT07319793 — Pre-DLI or Pro-DLI in Relapsed/Refractory Myeloid Neoplasms After HSCT; Not yet recruiting; Not Applicable; sponsor Peking University People's Hospital; enrollment 200.
• ChiCTR2500115218 — A phase II clinical study evaluating the efficacy and safety of Decitabine combined with Melphalan in newly diagnosed MDS-IB; Pending; Phase 2; sponsor First Affiliated Hospital Of Fujian Medical University, Self-Funded Plans Inc; enrollment 28.

Trial count is not product count. Observational studies, natural-history cohorts and multiple studies for one asset can inflate activity. Normalize records by phase, modality, mechanism, sponsor, recruitment status, geography, endpoint and exact subtype.

Compare against the likely future standard at launch. Whitespace may come from earlier treatment, genotype selection, durability, lower monitoring, safer chronic use or simpler delivery. Differentiation should be visible in protocol design and prospective analyses.

Recruitment risk requires site-density, testing, travel, competing-protocol and screen-failure assumptions. Natural-history evidence can reduce uncertainty but cannot substitute for controlled efficacy evidence when outcomes are variable.

Transactions and partnering attractiveness

No directly matched 2023–2026 transaction was returned. This may reflect limited partnering or broader asset-level indexing; add target and asset searches before valuation.

Separate upfront payments, milestones, royalties, options, bundled assets, platform rights and geographic scope. A defensible comparable set matches indication, target, modality, stage and territory, then explains remaining differences.

Partner readiness requires disease segmentation, target-validation chain, competition map, clinical plan, intellectual property, manufacturability evidence and a transparent risk-adjusted model. Outreach is strongest around a catalyst that retires material risk.

Low direct deal activity may represent whitespace, but can also signal difficult science or economics. Use broader therapeutic-area transactions only when relevance is explicit; rare-disease deals are not automatically interchangeable.

Market attractiveness and access

Attractiveness depends on diagnosis infrastructure, specialist concentration, treatment duration, setting, payer controls, alternatives, monitoring and reimbursement. Patient count is only one driver. Reliable identification and meaningful benefit can support a small population; fragmented diagnosis can undermine a larger one.

Build scenarios for diagnosed prevalence, eligible share, timing, competition, net price, persistence and penetration. Keep assumptions traceable and refresh them when new epidemiology, trial or transaction evidence appears.

Begin payer research before pivotal design so comparator, endpoint and follow-up support reimbursement as well as approval. Quality of life, caregiver burden, hospital use and diagnostic costs may be essential to the value case.

Risks, decision gates and recommendation

• Confirm a consistently diagnosed and recruitable population.
• Demonstrate C5 relevance in the selected phenotype.
• Connect engagement to a biomarker and meaningful endpoint.
• Refresh competition before every investment gate.
• Validate sites, testing, access, pricing and adoption.
• Treat zero-result searches as prompts for broader queries, not proof of absence.

Anemia, Refractory, With Excess of Blasts merits continued milestone-based evaluation if a coherent subgroup can be identified, target modulation can be measured and benefit remains differentiated against future care. The current evidence supports targeted diligence rather than unconditional investment.

The business-development objective is a partner-ready thesis covering patient segment, mechanism, whitespace, development path and value-inflection milestones. Evidence gaps should remain visible rather than hidden in a composite score.

Methodology and source note

This report was assembled on August 26, 2026 using Patsnap MCP tools: disease_fetch, epidemiology_search, target_fetch, clinical_trial_search and drug_deal_search. Results reflect records returned on the access date and can change as databases update.

Weights are 40% unmet need, 25% inverse competition and 35% market attractiveness. Inputs include disease profile, epidemiology coverage, registered trials, development-drug counts and direct transactions. Rerun with synonyms, roll-ups, targets and assets before commitment.

Build evidence-backed indication strategy with Patsnap MCP

Connect disease, target, clinical-trial and transaction intelligence through the Patsnap Life Sciences MCP marketplace.

Conclusion

The central question for Anemia, Refractory, With Excess of Blasts is whether a biologically grounded therapy can deliver material benefit in an identifiable population and remain differentiated through launch. This evidence provides a starting map; the explicit gaps define the next diligence plan.